Increasing economic burden of tyrosine kinase inhibitor treatment failure by line of therapy in chronic myeloid leukemia

Lisa J. McGarry, Yaozhu J. Chen, Victoria Divino, Shibani Pokras, Catherine R. Taylor, Julie Munakata, Christopher C. Nieset, Hui Huang, Elias Jabbour, Daniel C Malone

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objective:To assess the economic burden of tyrosine kinase inhibitor (TKI) treatment failure in chronic myeloid leukemia (CML), by assessing all-cause health care resource use (HCRU) and costs in the year after treatment failure by line of therapy (LOT; 1L/2L/3L) using real-world data.Methods:Treatment episodes initiating a TKI of interest (index TKI) during June 2008-December 2011 were identified from the IMS PharMetrics Plus Health Plan Claims Database for adult patients with CML diagnosis (ICD-9-CM 205.1x), 120 days pre-index continuous enrollment (CE) and no clinical trial participation. Episodes experiencing treatment failure, defined as switch to a non-index TKI or discontinuation of index TKI (gap of ≥ 60 days), and with 1 year CE post-failure, were analyzed. LOT was determined by number of unique TKIs used in the pre-index. All-cause HCRU and costs (2012 USD) in the 1 year post-failure were assessed by LOT, and the comparisons between 1L and 2L failures were also adjusted using multivariate generalized linear models (GLMs) to control for underlying differences.Results:A total of 706 episodes were identified (518 1L; 180 2L; 8 3L). Unadjusted HCRU over 1 year post-failure increased significantly. This was accompanied by a significant increase in unadjusted mean costs for 2L failures vs. 1L failures ($99,624 vs. $78,667, p = 0.021, Δ$20,957). Following the adjustment using GLMs, adjusted mean costs were 38% higher (95% CI 1.14-1.68), driven primarily by use of medical services. In adjusted analyses, compared to 1L, 2L failures had: 45% more ambulatory visits (mean 31 vs. 21, 95% CI 1.26-1.66), 75% higher risk of hospitalization (33% vs. 23% hospitalized, 95% CI 1.16-2.64), and 73% higher medical costs (95% CI 1.31-2.29). Medical costs comprised a greater proportion of total costs in 2L vs. 1L (55% vs. 44%); pharmacy costs did not increase significantly.Conclusions:The economic burden over 1 year post TKI failure increased with each sequential line of TKI treatment failure.

Original languageEnglish (US)
Pages (from-to)289-299
Number of pages11
JournalCurrent Medical Research and Opinion
Volume32
Issue number2
DOIs
StatePublished - Feb 1 2016

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Treatment Failure
Protein-Tyrosine Kinases
Economics
Costs and Cost Analysis
Health Resources
Therapeutics
Delivery of Health Care
Linear Models
International Classification of Diseases
Hospitalization
Clinical Trials
Databases
Health

Keywords

  • Chronic myeloid leukemia
  • Cost analysis
  • Economic cost
  • Health services research
  • Retrospective data
  • Treatment failure

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Increasing economic burden of tyrosine kinase inhibitor treatment failure by line of therapy in chronic myeloid leukemia. / McGarry, Lisa J.; Chen, Yaozhu J.; Divino, Victoria; Pokras, Shibani; Taylor, Catherine R.; Munakata, Julie; Nieset, Christopher C.; Huang, Hui; Jabbour, Elias; Malone, Daniel C.

In: Current Medical Research and Opinion, Vol. 32, No. 2, 01.02.2016, p. 289-299.

Research output: Contribution to journalArticle

McGarry, LJ, Chen, YJ, Divino, V, Pokras, S, Taylor, CR, Munakata, J, Nieset, CC, Huang, H, Jabbour, E & Malone, DC 2016, 'Increasing economic burden of tyrosine kinase inhibitor treatment failure by line of therapy in chronic myeloid leukemia', Current Medical Research and Opinion, vol. 32, no. 2, pp. 289-299. https://doi.org/10.1185/03007995.2015.1120189
McGarry, Lisa J. ; Chen, Yaozhu J. ; Divino, Victoria ; Pokras, Shibani ; Taylor, Catherine R. ; Munakata, Julie ; Nieset, Christopher C. ; Huang, Hui ; Jabbour, Elias ; Malone, Daniel C. / Increasing economic burden of tyrosine kinase inhibitor treatment failure by line of therapy in chronic myeloid leukemia. In: Current Medical Research and Opinion. 2016 ; Vol. 32, No. 2. pp. 289-299.
@article{90d7d58c5ed249a3a342910b447419f6,
title = "Increasing economic burden of tyrosine kinase inhibitor treatment failure by line of therapy in chronic myeloid leukemia",
abstract = "Objective:To assess the economic burden of tyrosine kinase inhibitor (TKI) treatment failure in chronic myeloid leukemia (CML), by assessing all-cause health care resource use (HCRU) and costs in the year after treatment failure by line of therapy (LOT; 1L/2L/3L) using real-world data.Methods:Treatment episodes initiating a TKI of interest (index TKI) during June 2008-December 2011 were identified from the IMS PharMetrics Plus Health Plan Claims Database for adult patients with CML diagnosis (ICD-9-CM 205.1x), 120 days pre-index continuous enrollment (CE) and no clinical trial participation. Episodes experiencing treatment failure, defined as switch to a non-index TKI or discontinuation of index TKI (gap of ≥ 60 days), and with 1 year CE post-failure, were analyzed. LOT was determined by number of unique TKIs used in the pre-index. All-cause HCRU and costs (2012 USD) in the 1 year post-failure were assessed by LOT, and the comparisons between 1L and 2L failures were also adjusted using multivariate generalized linear models (GLMs) to control for underlying differences.Results:A total of 706 episodes were identified (518 1L; 180 2L; 8 3L). Unadjusted HCRU over 1 year post-failure increased significantly. This was accompanied by a significant increase in unadjusted mean costs for 2L failures vs. 1L failures ($99,624 vs. $78,667, p = 0.021, Δ$20,957). Following the adjustment using GLMs, adjusted mean costs were 38{\%} higher (95{\%} CI 1.14-1.68), driven primarily by use of medical services. In adjusted analyses, compared to 1L, 2L failures had: 45{\%} more ambulatory visits (mean 31 vs. 21, 95{\%} CI 1.26-1.66), 75{\%} higher risk of hospitalization (33{\%} vs. 23{\%} hospitalized, 95{\%} CI 1.16-2.64), and 73{\%} higher medical costs (95{\%} CI 1.31-2.29). Medical costs comprised a greater proportion of total costs in 2L vs. 1L (55{\%} vs. 44{\%}); pharmacy costs did not increase significantly.Conclusions:The economic burden over 1 year post TKI failure increased with each sequential line of TKI treatment failure.",
keywords = "Chronic myeloid leukemia, Cost analysis, Economic cost, Health services research, Retrospective data, Treatment failure",
author = "McGarry, {Lisa J.} and Chen, {Yaozhu J.} and Victoria Divino and Shibani Pokras and Taylor, {Catherine R.} and Julie Munakata and Nieset, {Christopher C.} and Hui Huang and Elias Jabbour and Malone, {Daniel C}",
year = "2016",
month = "2",
day = "1",
doi = "10.1185/03007995.2015.1120189",
language = "English (US)",
volume = "32",
pages = "289--299",
journal = "Current Medical Research and Opinion",
issn = "0300-7995",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Increasing economic burden of tyrosine kinase inhibitor treatment failure by line of therapy in chronic myeloid leukemia

AU - McGarry, Lisa J.

AU - Chen, Yaozhu J.

AU - Divino, Victoria

AU - Pokras, Shibani

AU - Taylor, Catherine R.

AU - Munakata, Julie

AU - Nieset, Christopher C.

AU - Huang, Hui

AU - Jabbour, Elias

AU - Malone, Daniel C

PY - 2016/2/1

Y1 - 2016/2/1

N2 - Objective:To assess the economic burden of tyrosine kinase inhibitor (TKI) treatment failure in chronic myeloid leukemia (CML), by assessing all-cause health care resource use (HCRU) and costs in the year after treatment failure by line of therapy (LOT; 1L/2L/3L) using real-world data.Methods:Treatment episodes initiating a TKI of interest (index TKI) during June 2008-December 2011 were identified from the IMS PharMetrics Plus Health Plan Claims Database for adult patients with CML diagnosis (ICD-9-CM 205.1x), 120 days pre-index continuous enrollment (CE) and no clinical trial participation. Episodes experiencing treatment failure, defined as switch to a non-index TKI or discontinuation of index TKI (gap of ≥ 60 days), and with 1 year CE post-failure, were analyzed. LOT was determined by number of unique TKIs used in the pre-index. All-cause HCRU and costs (2012 USD) in the 1 year post-failure were assessed by LOT, and the comparisons between 1L and 2L failures were also adjusted using multivariate generalized linear models (GLMs) to control for underlying differences.Results:A total of 706 episodes were identified (518 1L; 180 2L; 8 3L). Unadjusted HCRU over 1 year post-failure increased significantly. This was accompanied by a significant increase in unadjusted mean costs for 2L failures vs. 1L failures ($99,624 vs. $78,667, p = 0.021, Δ$20,957). Following the adjustment using GLMs, adjusted mean costs were 38% higher (95% CI 1.14-1.68), driven primarily by use of medical services. In adjusted analyses, compared to 1L, 2L failures had: 45% more ambulatory visits (mean 31 vs. 21, 95% CI 1.26-1.66), 75% higher risk of hospitalization (33% vs. 23% hospitalized, 95% CI 1.16-2.64), and 73% higher medical costs (95% CI 1.31-2.29). Medical costs comprised a greater proportion of total costs in 2L vs. 1L (55% vs. 44%); pharmacy costs did not increase significantly.Conclusions:The economic burden over 1 year post TKI failure increased with each sequential line of TKI treatment failure.

AB - Objective:To assess the economic burden of tyrosine kinase inhibitor (TKI) treatment failure in chronic myeloid leukemia (CML), by assessing all-cause health care resource use (HCRU) and costs in the year after treatment failure by line of therapy (LOT; 1L/2L/3L) using real-world data.Methods:Treatment episodes initiating a TKI of interest (index TKI) during June 2008-December 2011 were identified from the IMS PharMetrics Plus Health Plan Claims Database for adult patients with CML diagnosis (ICD-9-CM 205.1x), 120 days pre-index continuous enrollment (CE) and no clinical trial participation. Episodes experiencing treatment failure, defined as switch to a non-index TKI or discontinuation of index TKI (gap of ≥ 60 days), and with 1 year CE post-failure, were analyzed. LOT was determined by number of unique TKIs used in the pre-index. All-cause HCRU and costs (2012 USD) in the 1 year post-failure were assessed by LOT, and the comparisons between 1L and 2L failures were also adjusted using multivariate generalized linear models (GLMs) to control for underlying differences.Results:A total of 706 episodes were identified (518 1L; 180 2L; 8 3L). Unadjusted HCRU over 1 year post-failure increased significantly. This was accompanied by a significant increase in unadjusted mean costs for 2L failures vs. 1L failures ($99,624 vs. $78,667, p = 0.021, Δ$20,957). Following the adjustment using GLMs, adjusted mean costs were 38% higher (95% CI 1.14-1.68), driven primarily by use of medical services. In adjusted analyses, compared to 1L, 2L failures had: 45% more ambulatory visits (mean 31 vs. 21, 95% CI 1.26-1.66), 75% higher risk of hospitalization (33% vs. 23% hospitalized, 95% CI 1.16-2.64), and 73% higher medical costs (95% CI 1.31-2.29). Medical costs comprised a greater proportion of total costs in 2L vs. 1L (55% vs. 44%); pharmacy costs did not increase significantly.Conclusions:The economic burden over 1 year post TKI failure increased with each sequential line of TKI treatment failure.

KW - Chronic myeloid leukemia

KW - Cost analysis

KW - Economic cost

KW - Health services research

KW - Retrospective data

KW - Treatment failure

UR - http://www.scopus.com/inward/record.url?scp=84955170127&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955170127&partnerID=8YFLogxK

U2 - 10.1185/03007995.2015.1120189

DO - 10.1185/03007995.2015.1120189

M3 - Article

C2 - 26566171

AN - SCOPUS:84955170127

VL - 32

SP - 289

EP - 299

JO - Current Medical Research and Opinion

JF - Current Medical Research and Opinion

SN - 0300-7995

IS - 2

ER -